Shu‐Wei Chou

ORCID: 0000-0002-4562-6002
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Acute Lymphoblastic Leukemia research
  • Acute Myeloid Leukemia Research
  • Neuroblastoma Research and Treatments
  • Hematopoietic Stem Cell Transplantation
  • Childhood Cancer Survivors' Quality of Life
  • Chronic Lymphocytic Leukemia Research
  • Cancer, Hypoxia, and Metabolism
  • Cancer therapeutics and mechanisms
  • Lymphoma Diagnosis and Treatment
  • Adolescent and Pediatric Healthcare
  • Hemoglobinopathies and Related Disorders
  • Chronic Myeloid Leukemia Treatments
  • Corrosion Behavior and Inhibition
  • Concrete Corrosion and Durability
  • Copper Interconnects and Reliability
  • Synthesis of Tetrazole Derivatives
  • Autoimmune and Inflammatory Disorders Research
  • Blood groups and transfusion
  • Blood disorders and treatments
  • Chromatin Remodeling and Cancer
  • Parvovirus B19 Infection Studies
  • Single-cell and spatial transcriptomics
  • Glioma Diagnosis and Treatment
  • Inorganic and Organometallic Chemistry
  • Platelet Disorders and Treatments

National Taiwan University
2022-2025

National Taiwan University Hospital
2018-2024

Pediatrics and Genetics
2021

Tatung University
2010-2013

Abstract Graft-versus-host disease (GVHD) is a major concern for patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Ruxolitinib has been proven effective in treating adult steroid-refractory GVHD; however, studies on pediatric are relatively scarce. Thus, this single-center study evaluated the efficacy and safety of ruxolitinib with GVHD. We retrospectively reviewed data aged < 18 years who underwent HSCT received treatment either acute GVHD (aGVHD) or chronic...

10.1007/s00277-025-06225-0 article EN cc-by Annals of Hematology 2025-02-04

To investigate the relations between anaplastic lymphoma kinase (ALK) and v-myc myelocytomatosis viral related oncogene neuroblastoma derived homolog (MYCN) protein expression their prognostic roles in tumours.Sixty-one tumours obtained at diagnosis were stained with anti-MYCN anti-ALK antibodies by immunohistochemical staining. The correlations of MYCN, ALK clinicopathological biological variables analysed.High could be detected 25 (41%) high MYCN 24 (39.3%) 61 tumours, respectively....

10.1136/jclinpath-2019-206063 article EN Journal of Clinical Pathology 2019-09-21

Abstract Context Patients with thalassemia major (TM) have a lower bone mineral density (BMD) and higher risk of fracture than the general population. The possible mechanisms include anemia, iron overload, malnutrition, hormonal deficiency, but these not been thoroughly investigated. Objective To identify factors related to BMD in adult TM patients provide human evidence for proposed mechanisms. Design Retrospective study. Setting Referral center. Twenty-nine β-TM, aged 23 44 years who were...

10.1210/clinem/dgz309 article EN The Journal of Clinical Endocrinology & Metabolism 2020-01-07

This retrospective study aimed to determine the prognostic value of imaging parameters derived from midtherapy 18F-fluorodihydroxyphenylalanine (18F-DOPA) and 18F-FDG PET in pediatric patients with stage 3-4 neuroblastoma.We enrolled 32 neuroblastoma who underwent 18F-DOPA PET/CT scans before after 3 chemotherapy cycles. We measured metabolic volumetric applied a burden scoring system evaluate primary tumor extent soft tissue metastases that bone/bone marrow involvement. The associations...

10.1097/rlu.0000000000003972 article EN Clinical Nuclear Medicine 2021-12-07

Neuroblastoma (NB) is a childhood tumor derived from the sympathoadrenal lineage of neural crest progenitor cells. Core 1 β1,3-galactosyltransferase (C1GALT1) controls crucial step GalNAc-type O-glycosylation, and its altered expression affects cancer behaviors. However, role C1GALT1 in NB tumors remains unclear. Our data showed that was significantly associated with differentiated histology, correlated TrkA expression, predicted good prognosis independently NB. Downregulation promotes...

10.1038/s41389-022-00383-w article EN cc-by Oncogenesis 2022-02-15

Abstract Background Neuroblastoma varies widely in risk. Risk indicators infants with incidental neuroblastoma refine treatment confidence for observation or intervention. The potential of functional imaging, particularly PET/CT, remains to be defined. Procedure A retrospective review under 18 months diagnosed from 2008 May 2022 our institute was conducted. Before October 2015, patients were treated similarly symptomatic cases, undergoing biopsy surgical excision upon diagnosis (early...

10.1002/pbc.30983 article EN Pediatric Blood & Cancer 2024-04-11

Abstract Mercaptopurine intolerance is an adverse effect of mercaptopurine administration in pediatric acute lymphoblastic leukemia. Recently, NUDT15 variants were identified as a major determinant intolerance. Two variants, c.36_37insGGAGTC and c.415C > T, are located on exons 1 3, respectively. Patients with heterozygous T can be either compound two different alleles or both the same allele. Because patients biallelic extremely sensitive to mercaptopurine, clinical identification...

10.1038/s41598-020-71468-y article EN cc-by Scientific Reports 2020-09-01

Hemophagocytic lymphohistiocytosis (HLH), a rarely occurring syndrome with various triggers, is associated early mortality. Owing to lack of sufficient corresponding data in Taiwan, this study aimed identify the outcome and potential factors 180-day mortality pediatric HLH. This retrospective analyzed clinical laboratory on patients diagnosed HLH at our institute (1995–2019). Logistic regression analysis was conducted determine associations between Overall, 48 had HLH; their median age...

10.1016/j.jfma.2020.10.026 article EN cc-by-nc-nd Journal of the Formosan Medical Association 2020-11-17

Abstract Improvement in outcomes of children with acute myeloid leukemia (AML) is attributed to several refinements clinical management. We evaluated treatment Taiwanese pediatric AML patients the past 20 years. Overall, 860 de novo aged 0–18 years and registered Childhood Cancer Foundation R.O.C during January 1996–December 2019 were included. Survival analysis was performed identify factors that improved outcomes. Regardless modalities used, 2008–2019 had better 5-year event-free survival...

10.1038/s41598-021-85321-3 article EN cc-by Scientific Reports 2021-03-15

Abstract Background This study analyzed data from two consecutive protocols for children newly diagnosed with acute lymphoblastic leukemia (ALL) to determine the clinical impact of minimal/measurable residual disease (MRD) and recently identified tumor genetic subtypes. Methods Genetic subtypes were determined by sequential approaches including DNA indexing, reverse transcriptase–polymerase chain reaction, multiplex ligation‐dependent probe amplification, RNA‐sequencing. MRD was assessed...

10.1002/cncr.34606 article EN Cancer 2022-12-20

Taiwan Pediatric Oncology Group (TPOG) initiated two consecutive protocols for treating pediatric patients with rhabdomyosarcoma since 1995. However, the results have not been analyzed and reported yet. The aim of this study is to investigate treatment these in our hospital assess whether are comparable other large-scaled studies. Treatment according TPOG at National University Hospital began Between 1995 2006, were treated by RMS 95 protocol, which was based on IRS-III/IV. After 2007, 2007...

10.1016/j.jfma.2018.05.015 article EN cc-by-nc-nd Journal of the Formosan Medical Association 2018-06-11

Hematopoietic stem cell transplantation (HSCT) with a matched sibling donor is the first-line therapy for pediatric aplastic anemia (AA). Whether to perform an alternative HSCT or use immunosuppressive (IST) including anti-thymocyte globulin (ATG) still unclear if suitable not available. IST concomitant eltrombopag, thrombopoietin receptor agonist, shows good response in adult.1 However, data of eltrombopag limited low prevalence AA, showing equivocal result.

10.1016/j.pedneo.2021.07.002 article EN cc-by-nc-nd Pediatrics & Neonatology 2021-07-30

Neuroblastoma is a pediatric malignancy with heterogeneous clinical outcomes. Our aim was to identify prognostic genetic markers for patients neuroblastoma, who were treated the Taiwan Pediatric Oncology Group (TPOG) neuroblastoma N2002 protocol, improve risk stratification and inform treatment.

10.1002/pbc.31176 article EN Pediatric Blood & Cancer 2024-07-05

Genetic changes in juvenile myelomonocytic leukemia (JMML) determine distinct subtypes, treatments, and outcomes. JMML with germline CBL mutation somatic NRAS possibly achieves spontaneous remission, but hematopoietic stem cell transplantation is indicated for other subtypes of JMML. We hereby report a child harboring (c.1111T>C) an NF1 variant (c.3352A>G) concurrently. After evaluation, we considered that the was not major contributor. one year observation, this case had no signs disease...

10.1016/j.jfma.2020.08.034 article EN cc-by-nc-nd Journal of the Formosan Medical Association 2020-09-12

In this work, the synergistic effect of 2-amino-5-(ethylthio)-1,3,4-thiadiazole (AETD) and chloride ion (Cl-) in a phosphate-based electrolyte was systemically studied. The results from X-ray photoelectron spectrometer indicate that Cl- indeed incorporated into AETD-containing passive film. According to extensive electrochemical material analyses, inhibition capability Cl--incorporated AETD film demonstrated superior corrosion resistance for Cu anodic dissolution compared alone due formation...

10.1016/s1452-3981(23)14707-9 article EN cc-by-nc-nd International Journal of Electrochemical Science 2013-04-01

Abstract Background Medulloblastoma (MB) is commonly classified into four molecular groups, that is, WNT, SHH, group 3, and 4, for prognostic therapeutic purposes. Methods Here we applied immunohistochemistry (IHC) RNA sequencing (RNA‐seq) the classification of MB, utilized multiplex ligation‐dependent probe amplification (MLPA) to determine chromosomal alterations specific gene amplifications. Results We retrospectively enrolled 37 pediatric MB patients. Twenty‐three had genomic material...

10.1002/pbc.29569 article EN Pediatric Blood & Cancer 2022-02-04

Genetic changes in juvenile myelomonocytic leukemia (JMML) determine distinct subtypes, treatments and outcomes. JMML with germline CBL mutation somatic NRAS possibly achieves spontaneous remission, but hematopoietic stem cell transplantation is indicated for other subtypes of JMML. We hereby report a child harboring (c.1111T>C) an NF1 variant (c.3352A>G) concurrently. After evaluation, we considered the not major contributor. one year observation, this case had no signs disease progression....

10.22541/au.159050463.34708710 preprint EN Authorea (Authorea) 2020-05-26
Coming Soon ...